Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yile Zhou

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Cell Death & Disease|May 17, 2020
BIG1 controls macrophage pro-inflammatory responses through ARF3-mediated PI(4,5)P2 synthesisLixin Liu, Sulin Zhang, Yirui Wang, et al.
Oncotarget|April 29, 2017
Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cellsJian Chen, Qitian Mu, Xia Li, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 19, 2017
Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabineXia Li, Xiao Yan, Wenjian Guo, et al.
Journal of Cancer Research and Clinical Oncology|February 3, 2018
Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphomaXiao Yan, Yile Zhou, Shujuan Huang, et al.
Biomarker Research|December 5, 2023
Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AMLQing Ling, Yutong Zhou, Yu Qian, et al.
Cancer|October 8, 2025
Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter studyJian Huang, Rumeng Li, Tiejun Gong, et al.
British Journal of Haematology|March 25, 2021
Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemiaHuanping Wang, Yile Zhou, Xin Huang, et al.
British Journal of Haematology|May 26, 2023
Glutamate dehydrogenase 1: A novel metabolic target in inhibiting acute myeloid leukaemia progressionZhixin Ma, Wenle Ye, Jinghan Wang, et al.
Haematologica|April 14, 2018
<i>Setd2</i> regulates quiescence and differentiation of adult hematopoietic stem cells by restricting RNA polymerase II elongationYile Zhou, Xiaomei Yan, Xiaomin Feng, et al.
Ebiomedicine|November 26, 2018
High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effectsXia Li, Chenying Li, Jingrui Jin, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Cell Death & Disease|May 17, 2020
BIG1 controls macrophage pro-inflammatory responses through ARF3-mediated PI(4,5)P2 synthesisLixin Liu, Sulin Zhang, Yirui Wang, et al.
Oncotarget|April 29, 2017
Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cellsJian Chen, Qitian Mu, Xia Li, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 19, 2017
Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabineXia Li, Xiao Yan, Wenjian Guo, et al.
Journal of Cancer Research and Clinical Oncology|February 3, 2018
Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphomaXiao Yan, Yile Zhou, Shujuan Huang, et al.
Biomarker Research|December 5, 2023
Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AMLQing Ling, Yutong Zhou, Yu Qian, et al.
Cancer|October 8, 2025
Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter studyJian Huang, Rumeng Li, Tiejun Gong, et al.
British Journal of Haematology|March 25, 2021
Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemiaHuanping Wang, Yile Zhou, Xin Huang, et al.
British Journal of Haematology|May 26, 2023
Glutamate dehydrogenase 1: A novel metabolic target in inhibiting acute myeloid leukaemia progressionZhixin Ma, Wenle Ye, Jinghan Wang, et al.
Haematologica|April 14, 2018
<i>Setd2</i> regulates quiescence and differentiation of adult hematopoietic stem cells by restricting RNA polymerase II elongationYile Zhou, Xiaomei Yan, Xiaomin Feng, et al.
Ebiomedicine|November 26, 2018
High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effectsXia Li, Chenying Li, Jingrui Jin, et al.
Pageof 5